
Jaguar Health Inc JAGX.OQ JAGX.O is expected to show a rise in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025
The San Francisco California-based company is expected to report a 20.0% increase in revenue to $2.821 million from $2.35 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Jaguar Health Inc is for a loss of $18.00 per share.
The one available analyst rating on the shares is "strong buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Jaguar Health Inc is $16.00, above its last closing price of $8.70.
This summary was machine generated May 9 at 14:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)